Apelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival[1][2].
Apelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.
The apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:
| Peptide | Amino Acids | Relative Abundance | Receptor Affinity |
|---|---|---|---|
| Apelin-36 | 36 | Lowest | Lowest |
| Apelin-16 | 16 | Low | Moderate |
| Apelin-13 | 13 | Highest in brain | Highest |
| Apelin-12 | 12 | Moderate | High |
Apelin-13 and its stable analog [Pyr^1]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.
The APJ receptor is a Class A GPCR that:
Apelin-13 promotes autophagy through AMPK and mTOR signaling pathways[3]:
This autophagy enhancement is particularly relevant for:
Apelin-13 protects BBB integrity through multiple mechanisms[4]:
BBB protection is critical for:
Apelin modulates neuroinflammation through[5]:
Apelin-13 promotes mitochondrial health:
Neuroprotective signaling through:
Apelin-13 has multiple beneficial effects in AD models[6][7]:
| Effect | Mechanism | Evidence |
|---|---|---|
| Amyloid Reduction | Enhanced autophagy | Mouse models |
| Tau Modification | GSK-3β inhibition | Cell culture |
| Synaptic Protection | CREB/BDNF | In vivo |
| Cognitive Improvement | Multiple | Behavioral tests |
Apelin-13 shows neuroprotection in PD models[8]:
In ALS models, apelin shows[9]:
Apelin modulation may benefit 4R-tauopathies:
| Compound | Type | Status | Notes |
|---|---|---|---|
| Apelin-13 | Peptide | Research | Unstable, rapid degradation |
| [Pyr^1]-Apelin-13 | Peptide | Research | More stable analog |
| Small Molecule Agonists | Small molecule | Preclinical | Oral bioavailability |
| AAV-APJ | Gene therapy | Preclinical | Long-term expression |
Modified analogs under development:
Currently limited clinical trial data for CNS applications:
| Strategy | Approach | Advantages | Limitations |
|---|---|---|---|
| Intranasal | Direct to CNS | Bypasses BBB | Limited distribution |
| AAV Vector | Gene delivery | Long-term expression | Immunogenicity |
| Exosomes | Cell-derived | BBB penetration | Manufacturing |
| Small Molecule | Oral delivery | Easy administration | Less selective |
Apelin-13 and apelin-36 in brain function. Nat Rev Neurosci. 2012. ↩︎
Apelin and neurodegeneration. J Neurochem. 2014. ↩︎
Apelin-13 and autophagy in neurodegeneration. Autophagy. 2019. ↩︎
Apelin-13 and blood-brain barrier. J Cereb Blood Flow Metab. 2018. ↩︎
Apelin receptor modulation and neuroinflammation. J Neuroinflammation. 2024. ↩︎
Apelin in Alzheimer's disease. Brain Res Bull. 2016. ↩︎
Apelin-13 in tauopathy models. Acta Neuropathol Commun. 2023. ↩︎
Apelin-13 neuroprotection in Parkinson's disease. Neuropharmacology. 2017. ↩︎
Apelin in ALS. Exp Neurol. 2018. ↩︎